Abstract 910P
Background
Parotid mucoepidermoid carcinoma (P-MEC) is a major histopathological subtype of salivary gland cancer, characterized by heterogeneity and complexity. Traditional clinical models and treatment plans are limited in providing personalized treatment recommendations and clinical management. This study aims to develop a machine learning-based prognostic model to improve survival rate prediction accuracy for P-MEC patients.
Methods
We used SEER database data (2004-2015) for 882 postoperative P-MEC patients. Single-factor Cox regression and four machine learning algorithms (Random Forest, LASSO, XGBoost, Best Subset Regression) were employed for variable selection and importance evaluation. The optimal variable selection model was determined using stepwise backward regression, AIC, and AUC. Bootstrap resampling was applied for internal validation.The model's prediction accuracy was assessed through C-index, ROC curve, and calibration curve. The clinical utility of the model was evaluated via DCA.
Results
The 3-, 5-, and 10-year OS rates for postoperative P-MEC patients were 0.887, 0.841, and 0.753. XGBoost, BSR, and LASSO demonstrated good predictive performance in variable selection and identified 7 independent prognostic factors: age, pathological grade, T stage, N stage, radiation therapy, chemotherapy, and marital status. A nomogram was developed based on the identified predictive variables. Internal validation with 1000 bootstrap resamples yielded consistent results for C-index (3-year, 0.841, 95%CI=0.839-0.844; 5-year, 0.842, 95%CI=0.840-0.845) and AUC (3-year, 0.858, 95%CI=0.856-0.860; 5-year, 0.872, 95%CI=0.870-0.875). The calibration plot indicated good prediction fit.
Conclusions
This study identified age, pathological grade, T stage, N stage, radiation therapy, chemotherapy, and marital status as independent prognostic factors in postoperative P-MEC patients. Machine learning algorithms outperformed traditional analysis methods in variable selection, predictive performance, and variable importance visualization. The developed machine learning-based nomogram offers high accuracy, robust calibration, and clinical application value for postoperative P-MEC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
899P - Impact of COVID-19 pandemic on treatment and survival in head and neck squamous cell carcinoma (HNSCC) patients (IMPACCT Study)
Presenter: Berta Vilar Anglada
Session: Poster session 12
900P - COVID-19 in patients with head and neck cancers (HERODOTUS): An international, registry-based, cohort study
Presenter: Amanda Psyrri
Session: Poster session 12
901P - Gut microbiome metagenomics and toxicity outcomes from chemoradiation therapy in head and neck squamous cell carcinoma
Presenter: Antoine Desilets
Session: Poster session 12
902P - Cisplatin-induced ototoxicity in head and neck cancer: The patterns and prediction
Presenter: Chiaki Suzuki
Session: Poster session 12
903P - AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes
Presenter: Renata Ferrarotto
Session: Poster session 12
904P - Retrospective analysis of adjuvant systemic anti-hormonal therapy for resected androgen receptor-positive (AR+) salivary duct carcinoma (SDC)
Presenter: Jetty Weijers
Session: Poster session 12
905P - Hot topics in salivary gland carcinomas treatment: An EORTC young investigator and early career investigator survey
Presenter: Luigi Lorini
Session: Poster session 12
906P - Multi-parameter flow cytometry analysis of circulating immune cell populations in recurrent/metastatic adenoid cystic carcinoma
Presenter: Samuel Rack
Session: Poster session 12
907P - Radiosensitivity signature in adenoid cystic carcinoma (ACC) of salivary glands origin is associated with ACC type II
Presenter: Laura Locati
Session: Poster session 12
908P - Efficacy of NOTCH inhibitors (Ni) relative to prior systemic therapy or observation in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC)
Presenter: Camilla Hoff
Session: Poster session 12